World Health Organisation (WHO) continues successful collaboration with Paul-Ehrlich-Institut
![Pharmaceutical Biotechnology for Non-Biotechnologists](files/eca/userImages/training.img/Z-ECA-Pharmaceutical-Biotechnology-Non-Biotechnologists.jpg)
Recommendation
9/10 October 2024
Berlin, Germany
An Overview and Insight in Pharmaceutical Biotechnology
After eight years of successful collaboration as a "WHO Collaborating Centre for Quality Assurance of Blood Products and in vitro Diagnostic Devices" the World Health Organization (WHO) has confirmed that it will continue working with the Paul-Ehrlich-Institut (PEI) for another four years. The President of the Paul-Ehrlich Institut, Professor Klaus Cichutek, is proud that the institute is being recognised in this way: "PEI has achieved this thanks to its in-depth expertise in a wide range of areas connected with regulatory affairs and scientific research as well as its sustained and reliable support of the WHO’s activities". During his visit to the PEI on 1 July 2013, Daniel Bahr, the German Federal Minister of Health, confirmed that "The quality of the PEI's work is very highly appreciated by the WHO."
More details can be found in the PEI's press release entitled "World Health Organization (WHO) continues successful collaboration with Paul-Ehrlich-Institut".
Related GMP News
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China
07.05.2024Update of Guideline on Epidemiological Data
05.03.2024FDA Warning Letter on misbranded and unapproved Drugs